SCHEMBL7174643

SCHEMBL7174643

CCOC(=O)C(C(=O)c1c(C)cccc1C)c1ccccc1.O=[PH3]

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.48
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA9 Q16790 2/20 0.44
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44
KMT2A Q03164 1/20 0.44
TSHR P16473 2/20 0.43
PIN1 Q13526 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
CA7 P43166 1/20 0.39
CA14 Q9ULX7 1/20 0.39
GAA P10253 1/20 0.39
SLC6A9 P48067 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27484252 0.94 MMP8 (0.56) MMP8L3MBTL1CA12CA1CA2
SCHEMBL7184953 0.91 MMP8 (0.50) MMP8L3MBTL1CA12CA1CA2
SCHEMBL7180375 0.90 MMP8 (0.46) MMP8L3MBTL1SMN1; SMN2
SCHEMBL7186423 0.90 L3MBTL1 (0.49) MMP8L3MBTL1CA12CA1CA2
SCHEMBL7183564 0.89 MMP8 (0.54) MMP8L3MBTL1CA12CA1CA2
SCHEMBL7175336 0.88 TSHR (0.46) MMP8L3MBTL1NPC1TSHRSMN1; SMN2
SCHEMBL7175658 0.87 NPC1 (0.45) MMP8L3MBTL1NPC1KMT2ASMN1; SMN2
SCHEMBL7180529 0.87 ALDH1A1 (0.45) MMP8L3MBTL1MEN1KMT2ATSHR
SCHEMBL7183557 0.87 TSHR (0.47) MMP8L3MBTL1NPC1TSHRSMN1; SMN2
SCHEMBL7175563 0.86 MMP8 (0.54) MMP8L3MBTL1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MMP8 4404/4885L3MBTL1 302/4885CA12 1552/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MMP8 4586/4885L3MBTL1 126/4885CA12 1320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.